• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高血压合并高尿酸血症的管理：纳米技术方法的引入。

Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches.

机构信息

Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.

Department of Pharmacology, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Chennai, India.

出版信息

Ann Med. 2024 Dec;56(1):2352022. doi: 10.1080/07853890.2024.2352022. Epub 2024 May 16.

DOI:10.1080/07853890.2024.2352022
PMID:38753584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11100442/
Abstract

Uric acid (UA) levels in blood serum have been associated with hypertension, indicating a potential causal relationship between high serum UA levels and the progression of hypertension. Therefore, the reduction of serum UA level is considered a potential strategy for lowering and mitigating blood pressure. If an individual is at risk of developing or already manifesting elevated blood pressure, this intervention could be an integral part of a comprehensive treatment plan. By addressing hyperuricaemia, practitioners may subsidize the optimization of blood pressure regulation, which illustrates the importance of addressing UA levels as a valuable strategy within the broader context of hypertension management. In this analysis, we outlined the operational principles of effective xanthine oxidase inhibitors for the treatment of hyperuricaemia and hypertension, along with an exploration of the contribution of nanotechnology to this field.

摘要

血清尿酸（UA）水平与高血压有关，这表明高血清 UA 水平与高血压的进展之间存在潜在的因果关系。因此，降低血清 UA 水平被认为是降低和缓解血压的一种潜在策略。如果一个人有发生或已经表现出高血压的风险，这种干预可能是全面治疗计划的一个组成部分。通过治疗高尿酸血症，医生可以辅助优化血压调节，这说明了在高血压管理的更广泛背景下，将 UA 水平作为一种有价值的策略进行处理的重要性。在这项分析中，我们概述了有效黄嘌呤氧化酶抑制剂治疗高尿酸血症和高血压的作用原理，并探讨了纳米技术在这一领域的贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/4df040d5c9d5/IANN_A_2352022_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/d9f0114fce42/IANN_A_2352022_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/2baa0b579b52/IANN_A_2352022_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/558a0ac07722/IANN_A_2352022_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/3aed682eee72/IANN_A_2352022_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/4df040d5c9d5/IANN_A_2352022_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/d9f0114fce42/IANN_A_2352022_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/2baa0b579b52/IANN_A_2352022_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/558a0ac07722/IANN_A_2352022_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/3aed682eee72/IANN_A_2352022_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2d9/11100442/4df040d5c9d5/IANN_A_2352022_F0005_C.jpg

相似文献

1
Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches.高血压合并高尿酸血症的管理：纳米技术方法的引入。
Ann Med. 2024 Dec;56(1):2352022. doi: 10.1080/07853890.2024.2352022. Epub 2024 May 16.
2
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.非布司他对高尿酸血症合并高血压患者动态血压的影响：一项 2 期随机安慰剂对照研究。
J Am Heart Assoc. 2017 Nov 4;6(11):e006683. doi: 10.1161/JAHA.117.006683.
3
Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.黄嘌呤氧化酶抑制剂对高尿酸血症高血压患者肾功能和血压的影响。
Hypertens Res. 2016 Aug;39(8):593-7. doi: 10.1038/hr.2016.37. Epub 2016 Apr 14.
4
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.使用黄嘌呤氧化酶抑制剂非布司他进行治疗可降低尿酸，并减轻实验性高尿酸血症中的全身性高血压和肾小球高血压。
Nephrol Dial Transplant. 2008 Apr;23(4):1179-85. doi: 10.1093/ndt/gfm783. Epub 2007 Nov 29.
5
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.黄嘌呤氧化酶抑制剂对血压和肾功能的影响。
Curr Hypertens Rep. 2017 Oct 25;19(12):95. doi: 10.1007/s11906-017-0793-3.
6
Lesinurad: A Review in Hyperuricaemia of Gout.雷西纳德：痛风高尿酸血症的综述
Drugs Aging. 2017 May;34(5):401-410. doi: 10.1007/s40266-017-0461-y.
7
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial.别嘌醇对新诊断原发性高血压青少年血压的影响：一项随机试验。
JAMA. 2008 Aug 27;300(8):924-32. doi: 10.1001/jama.300.8.924.
8
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.别嘌醇治疗肿瘤溶解综合征及其对血液系统恶性肿瘤患者嘌呤代谢物水平影响的单中心药代动力学和初步前瞻性研究。
Anticancer Res. 2014 Dec;34(12):7287-96.
9
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.血清尿酸降低疗法：在高尿酸血症管理中我们正走向何方以及尿酸酶的潜在作用。
Curr Rheumatol Rep. 2004 Jun;6(3):240-7. doi: 10.1007/s11926-004-0075-3.
10
Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.降尿酸治疗对血压的影响：系统评价与荟萃分析
Ann Med. 2017 Mar;49(2):142-156. doi: 10.1080/07853890.2016.1243803. Epub 2016 Nov 12.

引用本文的文献

1
Causal impact of human blood metabolites and metabolic pathways on serum uric acid and gout: a mendelian randomization study.人类血液代谢物和代谢途径对血清尿酸和痛风的因果影响：一项孟德尔随机研究。
Front Endocrinol (Lausanne). 2024 Jul 4;15:1378645. doi: 10.3389/fendo.2024.1378645. eCollection 2024.

本文引用的文献

1
Nanocarriers in topical photodynamic therapy.纳米载体在局部光动力疗法中的应用。
Expert Opin Drug Deliv. 2024 Feb;21(2):279-307. doi: 10.1080/17425247.2024.2318460. Epub 2024 Feb 20.
2
Haemostatic potency of sodium alginate/aloe vera/sericin composite scaffolds - preparation, characterisation, and evaluation.藻酸钠/芦荟/丝胶复合材料支架的止血效力 - 制备、表征和评价。
Artif Cells Nanomed Biotechnol. 2024 Dec;52(1):35-45. doi: 10.1080/21691401.2023.2293784. Epub 2023 Dec 19.
3
Fabrication and optimization of febuxostat-loaded chitosan nanocarriers for better pharmacokinetics profile.
载非布司他壳聚糖纳米载体的制备及优化以改善药代动力学特征。
Int J Biol Macromol. 2024 Feb;257(Pt 1):128448. doi: 10.1016/j.ijbiomac.2023.128448. Epub 2023 Nov 30.
4
Intricate subcellular journey of nanoparticles to the enigmatic domains of endoplasmic reticulum.纳米颗粒错综复杂的亚细胞旅程进入内质网神秘的领域。
Drug Deliv. 2023 Dec;30(1):2284684. doi: 10.1080/10717544.2023.2284684. Epub 2023 Nov 21.
5
Size and charge effects of metal nanoclusters on antibacterial mechanisms.金属纳米团簇的尺寸和电荷对其抗菌机制的影响。
J Nanobiotechnology. 2023 Nov 15;21(1):428. doi: 10.1186/s12951-023-02208-3.
6
Cancer therapy with iRGD as a tumor-penetrating peptide.iRGD 作为穿膜肽的癌症治疗。
Bull Cancer. 2023 Dec;110(12):1288-1300. doi: 10.1016/j.bulcan.2023.08.009. Epub 2023 Oct 8.
7
The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation.URRAH（尿酸对心脏健康的作用）项目的结果：关注高尿酸血症与心血管和肾脏疾病的关系及其在代谢失调中的作用。
High Blood Press Cardiovasc Prev. 2023 Sep;30(5):411-425. doi: 10.1007/s40292-023-00602-4. Epub 2023 Oct 4.
8
The Role of Uric Acid in Human Health: Insights from the Gene.尿酸在人类健康中的作用：来自该基因的见解。
J Pers Med. 2023 Sep 20;13(9):1409. doi: 10.3390/jpm13091409.
9
Febuxostat alleviates Arsenic Trioxide-Induced renal injury in Rats: Insights on the crosstalk between NLRP3/TLR4, Sirt-1/NF-κB/TGF-β signaling Pathways, and miR-23b-3p, miR-181a-5b expression.非布司他减轻三氧化二砷诱导的大鼠肾损伤：NLRP3/TLR4、Sirt-1/NF-κB/TGF-β 信号通路及 miR-23b-3p、miR-181a-5b 表达的相互作用。
Biochem Pharmacol. 2023 Oct;216:115794. doi: 10.1016/j.bcp.2023.115794. Epub 2023 Sep 7.
10
Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase.别嘌醇和氧嘌呤醇在抑制黄嘌呤氧化还原酶的强度和机制方面存在差异。
J Biol Chem. 2023 Sep;299(9):105189. doi: 10.1016/j.jbc.2023.105189. Epub 2023 Aug 23.